

Accelerated Approvals and Confirmatory Studies

As of December 31, 2021




278

Accelerated Approvals



66%

Percentage of Accelerated Approvals for Oncology¹



4 years

Median conversion time to traditional approval over the life of the program

2.8 years

Median conversion time to traditional approval over the last decade

¹ 8 total “dangling” (studies have failed to confirm benefit) or “delinquent” (study deadlines have been missed)
Source: FDA, Postmarket Requirements and Commitments, <https://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm>